Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
Description
While chemoimmunotherapy is the current standard of care for initial treatment of mantle cell lymphoma (MCL), newer data suggests that there may be a role for a chemotherapy-free approach. We report 9-year follow up of a multi-center phase 2 study of
